<?xml version="1.0" encoding="UTF-8"?>
<p>Valacyclovir has a generally benign safety profile with minimally higher rates of headache and dizziness compared with placebo in controlled treatment trials.
 <xref rid="R28" ref-type="bibr">28</xref> In the post-marketing phase, initial double-blind followed by intermittent and continuous valacyclovir treatment for up to 7 years showed no major side effects.
 <xref rid="R34" ref-type="bibr">34 35</xref> Hallucinations, delirium and seizures can occur in less than 1% of patients with renal failure who are taking valacyclovir.
 <xref rid="R36" ref-type="bibr">36</xref>
</p>
